Medical device company Nexstim in Finland, has obtained CE mark approval for its non-invasive Navigated Brain therapy (NBT) system.
The system featuring MRI-based navigation allows users to visualize the electric field inside the patient’s brain and accurately target therapy.
Using pulsed magnetic fields, the non-systemic therapeutic device stimulates a specific region of the cerebral cortex which is involved the controlling mood and associated with depression.
In addition, the therapy is also indicated for use in patients to recover from stroke, as a supplement to conventional rehabilitation.
Studies conduced on navigated brain therapy, for treating depression, has been shown to be safe, well-tolerated and without the side-effects associated with oral antidepressants.
The company said the NBT system has not received clearance from the FDA and is not available for sale in the US.